



Greta E. Noland

Patent Agent

Tel 312.423.3449 gnoland@marshallip.com

Greta E. Noland builds and manages global patent portfolios for clients in the biotechnology and pharmaceutical industries. As a component of her portfolio management, Greta counsels clients in interference and appeal proceedings in the United States and guides clients through opposition, appeal, conflict and revocation proceedings in other countries. She also frequently performs due diligence analyses for intellectual property transactions and public stock offerings.

By virtue of working for academic, not-for-profit, private and public entities, her advice encompasses many perspectives important for product life cycle management. Greta achieves clients' goals by delivering creative, attentive service molded by thirty years of experience in the field.

Practices

- IP Litigation
- Patent Prosecution
- Post-Grant Patent Proceedings

Industries

- Biotechnology & Life Sciences
- Non-Profit Technology Transfer
- Pharmaceutical

Representative Experience

- Successful oppositions against a series of European patents relating to CRISPR-Cas9 systems
- Successful appeal relating to lack of formal entitlement to priority of a European patent relating to CRISPR-Cas9 systems
- Prosecuting U.S. patents to chimeric antigen receptors (CARs) and their use in treating cancer



 Completing due diligence analyses for a client's acquisition of a FDA-approved bone graft product

Greta has advanced clients' rights in such technologies as:

- CRISPR-Cas9 systems
- CAR T-cells
- Therapeutic and diagnostic antibody products
- Viral vectors for gene therapy and vaccines
- Novel gene products including cellular adhesion molecules, chemokines, hormones, G proteins, phosphodiesterases, phosphatases and kinases
- Genetic engineering of plants
- Gene regulation techniques

Education

- Northwestern University (M.S.)
 - Molecular Biology
- University of Notre Dame (B.S.)
 - Microbiology

Bar Admissions

U.S. Patent and Trademark Office

Background and Credentials

Greta was registered as a patent agent in 1991. Previously, she earned a B.S. in microbiology from the University of Notre Dame and an M.S. in molecular biology from Northwestern University.

Representative Matters

Adams (Monsanto)* v. Leemans (Bayer Crop Sciences)

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Barton v. Fischhoff* (Monsanto) v. Adang (Mycogen Plant Science)

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology



Birkenbach v. Godiska (ICOS Corporation)*

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Conflict re: Kirin-Amgen, Inc.*

Canadian Intellectual Property Office

Case Type(s): Conflict

Area(s) of practice: Pharmaceuticals

Conflict re: Monsanto Company*
Canadian Intellectual Property Office

Case Type(s): Conflict

Area(s) of practice: Biotechnology

Fraley (Monsanto)* v. Zambryski v. Anderson

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Fraley (Monsanto)* v. Comai

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Fraley (Monsanto)* v. Zambryski

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Godiska (ICOS Corporation)* v. Li (Human Genome Sciences)

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Pharmaceuticals

Invalidity Action re: Pfizer Research and Development Company

Canadian Federal Court

Area(s) of practice: Pharmaceuticals

Masinovsky (ICOS Corporation)* v. Newman v. Rice

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

Oppositions and Appeal on behalf of CRISPR Therapeutics AG* re: Broad Institute Inc., Massachusetts Institute of Technology and President and Fellows of Harvard College

European Patent Office

Case Type(s): Opposition, Appeal

Area(s) of practice: Biotechnology, CRISPR-Cas9



Oppositions re: Emmanuelle Charpentier*, The Regents of the University of California and University of

Vienna European Patent Office

Case Type(s): Opposition

Area(s) of practice: Biotechnology, CRISPR-Cas9

Opposition and Appeal re: Kirin-Amgen, Inc.*

European Patent Office

Case Type(s): Opposition, Appeal Area(s) of practice: Pharmaceuticals

Opposition and Appeal re: Pfizer Limited

European Patent Office

Case Type(s): Opposition, Appeal Area(s) of practice: Pharmaceuticals

Opposition and Appeal re: Protein Design Labs, Inc.

European Patent Office Case Type(s): Opposition

Area(s) of practice: Pharmaceuticals

Opposition and Federal Court Appeal re: Kirin-Amgen, Inc.*

Australian Patent Office and Federal Court

Case Type(s): Opposition, Appeal Area(s) of practice: Pharmaceuticals

Opposition and Appeal re: Amgen, Inc.*

European Patent Office Case Type(s): Opposition

Area(s) of practice: Pharmaceuticals

Opposition re: Genentech, Inc.

European Patent Office Case Type(s): Opposition

Area(s) of practice: Pharmaceuticals

Opposition re: Genetics Institute, Inc.

Australian Patent Office Case Type(s): Opposition

Area(s) of practice: Pharmaceuticals, Biotechnology

Opposition re: Kirin-Amgen, Inc.*

Israeli Patent Office

Case Type(s): Opposition

Area(s) of practice: Pharmaceuticals

Revocation and Amendment Proceedings re: Kirin-Amgen, Inc.*

The Court of the Commissioner of Patents for The Republic of South Africa

Area(s) of practice: Pharmaceuticals



Revocation and Appeal re: Pfizer Limited

UK High Court of Justice and Supreme Court of Judicature Court of Appeal

Case Type(s): Appeal

Area(s) of practice: Pharmaceuticals

Schilperoort v. Rogers (Monsanto)* v. Barton v. Zambryski

U.S. Patent Office

Case Type(s): Patent Interference Area(s) of practice: Biotechnology

The Broad Institute, Inc., Massachusetts Institute of Technology, and President and Fellows of Harvard College v. The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier*

U.S. Patent Trial and Appeal Board Case Type(s): Patent Interference

Area(s) of practice: CRISPR-Cas9 technology

Vanderbilt v. ICOS Corporation*

U.S. District Court

Case Type(s): Patent Litigation Area(s) of practice: Pharmaceuticals

*Party Represented